JP2013525420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525420A5 JP2013525420A5 JP2013506803A JP2013506803A JP2013525420A5 JP 2013525420 A5 JP2013525420 A5 JP 2013525420A5 JP 2013506803 A JP2013506803 A JP 2013506803A JP 2013506803 A JP2013506803 A JP 2013506803A JP 2013525420 A5 JP2013525420 A5 JP 2013525420A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- group
- set composition
- amount
- cause
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 8
- 208000006454 hepatitis Diseases 0.000 claims 7
- 231100000283 hepatitis Toxicity 0.000 claims 7
- 239000012678 infectious agent Substances 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 4
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 2
- 108010082126 Alanine transaminase Proteins 0.000 claims 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000589902 Leptospira Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010037688 Q fever Diseases 0.000 claims 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 1
- 238000007446 glucose tolerance test Methods 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 238000012317 liver biopsy Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32955410P | 2010-04-29 | 2010-04-29 | |
| US61/329,554 | 2010-04-29 | ||
| PCT/IB2011/051900 WO2011135544A2 (en) | 2010-04-29 | 2011-04-29 | Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016096494A Division JP2016172759A (ja) | 2010-04-29 | 2016-05-12 | 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525420A JP2013525420A (ja) | 2013-06-20 |
| JP2013525420A5 true JP2013525420A5 (https=) | 2014-05-29 |
Family
ID=44629291
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506803A Pending JP2013525420A (ja) | 2010-04-29 | 2011-04-29 | 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 |
| JP2016096494A Pending JP2016172759A (ja) | 2010-04-29 | 2016-05-12 | 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016096494A Pending JP2016172759A (ja) | 2010-04-29 | 2016-05-12 | 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130078238A1 (https=) |
| EP (1) | EP2563815A2 (https=) |
| JP (2) | JP2013525420A (https=) |
| KR (1) | KR20130066626A (https=) |
| CN (1) | CN103038256A (https=) |
| AU (1) | AU2011246893A1 (https=) |
| BR (1) | BR112012027531A2 (https=) |
| CA (1) | CA2804976A1 (https=) |
| WO (1) | WO2011135544A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4654210A (en) | 1979-04-26 | 1987-03-31 | Ortho Pharmaceutical Corporation | Methods and compositions using complement fixing monoclonal antibody to human T cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| WO1991006319A1 (en) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| AUPQ431299A0 (en) * | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
| US20050069546A1 (en) * | 2003-09-30 | 2005-03-31 | Yaron Ilan | Educated NKT cells and their uses in the treatment of immune-related disorders |
| US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| US8940479B2 (en) * | 2008-01-14 | 2015-01-27 | Cornell University | Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity |
| WO2009090656A2 (en) * | 2008-01-18 | 2009-07-23 | Hadasit Medical Research Services & Development Ltd. | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
-
2011
- 2011-04-29 KR KR1020127031085A patent/KR20130066626A/ko not_active Withdrawn
- 2011-04-29 WO PCT/IB2011/051900 patent/WO2011135544A2/en not_active Ceased
- 2011-04-29 JP JP2013506803A patent/JP2013525420A/ja active Pending
- 2011-04-29 CN CN2011800284648A patent/CN103038256A/zh active Pending
- 2011-04-29 US US13/635,119 patent/US20130078238A1/en not_active Abandoned
- 2011-04-29 CA CA2804976A patent/CA2804976A1/en not_active Abandoned
- 2011-04-29 BR BR112012027531A patent/BR112012027531A2/pt not_active IP Right Cessation
- 2011-04-29 AU AU2011246893A patent/AU2011246893A1/en not_active Abandoned
- 2011-04-29 EP EP11738285A patent/EP2563815A2/en not_active Withdrawn
-
2016
- 2016-05-12 JP JP2016096494A patent/JP2016172759A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525420A5 (https=) | ||
| CN105050622B (zh) | 针对呼吸道融合病毒f蛋白质的人类抗体及其使用方法 | |
| US10604559B2 (en) | Multi-valent hepatitis B virus antigen binding molecules and uses thereof | |
| Cashman et al. | The humoral immune response to HCV: understanding is key to vaccine development | |
| Kong et al. | Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design | |
| JP2022065140A (ja) | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 | |
| AU2013287516B2 (en) | An antibody composition for prevention or treatment of mutant hepatitis B virus infection | |
| Bessalah et al. | Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19) | |
| JP2020503844A (ja) | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 | |
| Wang et al. | A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey | |
| JP2017537084A5 (https=) | ||
| JP2012504602A5 (https=) | ||
| CA2738644A1 (en) | Hepatitis c antibodies and uses thereof | |
| CN104338132A (zh) | 一种病毒免疫治疗药物复合物及其用途 | |
| Jacobs | Neutralizing antibodies mediate virus-immune pathology of COVID-19 | |
| ME02280B (me) | Antagonisti toll-like receptora 3 | |
| JP2020517671A5 (https=) | ||
| Verstrepen et al. | Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies | |
| Wang et al. | A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy | |
| Haruna et al. | Local production of broadly cross‐reactive IgE against multiple fungal cell wall polysaccharides in patients with allergic fungal rhinosinusitis. | |
| Stoffel et al. | Immunogenicity of Twinrix™ in older adults: a critical analysis | |
| Mbani et al. | Enterovirus antibodies: friends and foes | |
| Patel et al. | Immunization with live human rhinovirus (HRV) 16 induces protection in cotton rats against HRV14 infection | |
| Luo et al. | Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F (ab′) 2 | |
| Liu et al. | Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges |